Biosimilar Medicines

Biosimilars/biosimilar medicines have been developing rapidly, promising to bring many benefits in the diagnosis, treatment, prevention of diseases, and human health improvement. Biosimilar is a medicine that is highly similar to an already licensed biological product (reference medicine). Although there are some minor differences in the inactive ingredients, there are no clinically significant differences in the purity, potency, and safety between the two products. The development of biosimilars is a challenging multistep process. Unlike "generic" medicine, the development of biosimilars requires comprehensive studies to demonstrate comparability to the reference medicine and to ensure safety and efficacy. Therefore, there are many unique characteristics in the research and development, biological activity testing, approval, and quality control of biosimilars. This review discusses the characteristics of biosimilar medicines and the challenges in their research, development, and approval.

Authors

Publication Details

Journal
VNU Journal of Science Medical and Pharmaceutical Sciences
Published
2025-03-19
DOI
https://doi.org/10.25073/2588-1132/vnumps.4751
Primary Topic
Biosimilars and Bioanalytical Methods
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Biosimilar Medicines

Nguyen Hue Linh, Dang Khoa Nguyen, Nguyễn Thanh Hải, Phạm Thị Huế et al.
VNU Journal of Science Medical and Pharmaceutical Sciences
Biosimilars and Bioanalytical Methods
article

Biosimilar Medicines

Nguyen Hue Linh, Dang Khoa Nguyen, Nguyễn Thanh Hải, Phạm Thị Huế, Vo Quoc Anh
article en

Abstract

Biosimilars/biosimilar medicines have been developing rapidly, promising to bring many benefits in the diagnosis, treatment, prevention of diseases, and human health improvement. Biosimilar is a medicine that is highly similar to an already licensed biological product (reference medicine). Although there are some minor differences in the inactive ingredients, there are no clinically significant differences in the purity, potency, and safety between the two products. The development of biosimilars is a challenging multistep process. Unlike "generic" medicine, the development of biosimilars requires comprehensive studies to demonstrate comparability to the reference medicine and to ensure safety and efficacy. Therefore, there are many unique characteristics in the research and development, biological activity testing, approval, and quality control of biosimilars. This review discusses the characteristics of biosimilar medicines and the challenges in their research, development, and approval.

VNU Journal of Science Medical and Pharmaceutical SciencesVol. 41(1)
Openalex Percentile: Top 94%
Biosimilars and Bioanalytical Methods
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.